date:May 10, 2012
ng on endocrine-related drug discovery and development before joining NuMe.
Its mission is to shift GI microbiome populations to favorably affect prediabetes by increasing insulin sensitivity, improving fasting glucose levels, increasing the production of satiety hormones, inhibiting the appetite hormone ghrelin, and making the body less efficient at absorbing calories.
Commercialization plan
The business plan is to develop consumer products containing NM504, either directly or via a strat